Syndax Q2 Revenue Surges 92% to $72.8M, Loss Narrows; Pipeline Expands with Two New Assets
SNDX sits 83% above its 52-week low of $9.68.
Summary
Syndax reported Q2 2026 revenue of $72.8 million, a 92% increase year-over-year, driven by Revuforj and Niktimvo. The net loss narrowed to $49.4 million, and cash reserves stand at $575 million. The company also disclosed two new pipeline assets and multiple upcoming clinical catalysts.
Key Events · Earnings and Guidance · SNDX
-
Revenue Nearly Doubles
Total revenue reached $72.8 million in Q2 2026, up 92% from $38.0 million in Q2 2025. Revuforj contributed $54.7 million (up 91%) and Niktimvo collaboration revenue was $18.1 million (up 93%).
-
Net Loss Narrows
Net loss improved to $49.4 million from $71.8 million a year ago, driven by revenue growth and disciplined spending. Operating expenses rose only 5% to $112.8 million.
-
Strong Cash Position
Cash, equivalents, and investments totaled $575.1 million at quarter-end, boosted by a $250 million convertible note offering in June 2026. The company believes this is sufficient to fund operations for the foreseeable future.
-
Pipeline Expansion
Syndax announced two new assets: SNDX-4321, a mutant-selective EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. Both are expected to enter the clinic in 2027.
Analysis · SNDX · Life Sciences
A strong commercial quarter saw Revuforj and Niktimvo revenues nearly double year-over-year, while operating losses shrank. The company ended the period with $575 million in cash, fortified by a $250 million convertible note offering, extending its runway. The 10-Q also details the recent addition of two new pipeline programs—SNDX-4321 for EGFR-mutant NSCLC and SNDX-62122 for myelofibrosis—and a slate of upcoming clinical data readouts that could drive further value. The combination of accelerating revenue, a fortified balance sheet, and pipeline expansion makes this a highly material update.
At the time of this filing, SNDX was trading at $17.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.68 to $25.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.